纳米微球药物缓释技术

纳米微球作为药物载体被越来越多地应用于医药领域,这一技术得到研究者的广泛重视。目前已有多种纳米微球制剂投入临床使用。纳米微球的深入研究具有重要的意义。我们概述了近年来纳米微球的研究及应用情况,展望了纳米微球药物载体缓释技术的应用前景及需要解决的问题。     

基于超高速摄影显微成像和超声散射的纳米包膜造影微泡包膜厚度估计

纳米包膜微泡和携带药物的生物微系统在超声成像和药物传递与释放等方面具有重要的应用价值。通过使用时间分辨率最小可达10ns的新型超高速显微成像装置,得到微泡在医用频率超声场中的半径振动曲线,对参数做灵敏度分析后,与理论预测结果做最小均方误差对比,经反向参数估计,获得包膜厚度估计值。结果表明,该技术在不破坏样品的务件下,能得到较为准确的包膜参数。     

长效缓释微球制剂生产技术的发展现状

长效缓释微球是将药物溶解或分散在高分子骨架材料中的微米级别的药物释放载体,这种新剂型可以显著降低给药频率,同时大分子材料的包裹可以提高药物的稳定性,降低药物的毒副作用,目前广泛应用在蛋白多肽等药物。已有一些用于治疗糖尿病、精神病、子宫内膜异位等疾病的长效缓释微球制剂被批准上市。然而,因为微球的制备工艺繁杂、质量控制困难,至今只在少数产品上应用,现在越来越多的口服难吸收的生物药物开始产品化,长效缓释微球在提高患者依从性方面备受瞩目。本综述对目前典型的微球制备技术做出分析和评判,以期对完善微球制备工艺有所帮助。     

包裹于PLGA微球中用于蛋白控释的多糖纳米颗粒

目的:研究包裹在PLGA微球中的多糖纳米颗粒在保护蛋白稳定性和改善药物体外释放行为方面的作用。方法:将模型药物BSA用低温诱导相分离方法担载于多糖纳米颗粒之中,后将其用水包油包固复乳法包裹于PLGA微球内。应用体积排阻色谱(SEC-HPLC)和红外色谱(FTIR)表征蛋白的稳定性,而且也研究了样品的体外释放行为。结果:这种方法能够很好的保护蛋白的稳定性,保持蛋白结构在制备过程中不会改变,而且改善了体外释放行为,减少了突释。结论:多糖纳米颗粒结合PLGA微球能够提供一种有效的解决蛋白控释的途径。     

超声靶向微泡破坏与载药/载基因纳米粒联合应用的生物物理学机制及应用研究进展

超声靶向微泡破坏(ultrasound-targeted microbubble destruction, UTMD)能够安全、高效、简便地递送药物与基因,是当前超声医学领域的研究热点,其机制主要涉及超声辐照微泡引起的空化效应及其二级效应、内吞作用与声辐射力。近年来,随着生物医学材料科学迅猛发展,纳米载药系统取材更加广泛,制备方法愈发精良,载药量日益提高。将纳米载药系统与UTMD进行联合,可以扬长避短,为肿瘤等多种疾病的治疗带来新的思路与希望。本文旨在对UTMD与载药/载基因纳米粒联合应用的生物物理学机制及应用研究进行综述并提出展望。     

壳聚糖携载质粒纳米微球体外转染兔关节软骨细胞的实验研究

目的：研究携载质粒的不同分子量的壳聚糖纳米微球的包裹率和保护DNA的能力,镜下观察其大小和形态,观察其对原代兔关节软骨细胞的转染效率。方法：利用酶消化法消化3周龄新西兰大白兔的关节软骨,贴壁培养原代兔关节软骨细胞。购买相对分子量在5K和800K之间的八种壳聚糖,利用表达增强型绿色荧光蛋白的质粒（pEGFP）作报告基因,通过复合凝聚法制备壳聚糖-质粒纳米微球。琼脂糖凝胶电泳、紫外分光光度计分析不同N/P比值对不同分子量壳聚糖和质粒的结合能力及包封率的影响;纳米粒度仪、透射电子显微镜和环境扫描电子显微镜考察纳米微球的粒径分布和形态;荧光显微镜观察壳聚糖纳米微球介导pEGFP在体外培养的兔关节软骨细胞中的表达情况;流失细胞仪计算具体转染效率。结果：①N/P值为4及4以上时,各分子量的壳聚糖可完全包裹质粒成球;N/P值为2时,分子量为5K、50K、85K仅部分包裹质粒,其余可完全包裹;N/P值为1时,各壳聚糖均与质粒部分包裹;N/P值为0.25时,各壳聚糖均与质粒完全分离。②纳米粒度仪分析得出：N/P值为4时,各分子量的壳聚糖纳米微球的平均粒径均在1微米以下,③透射电子显微镜和扫描电子显微镜均可观察到球形或不规则形的大小不同的微球。荧光显微镜可大致观察到绿色荧光蛋白在软骨细胞内表达的表达情况。④流式细胞仪得出具体转染效率,分子量为170K、250K和800K的壳聚糖纳米微球的转染效率均高于5K、50K和85K的壳聚糖纳米微球,其中800K的壳聚糖纳米微球与脂质体相当（差异有统计学意义,P〈0.05）。结论：与脂质体相比,N/P比值为4时,相对分子量为800k的壳聚糖纳米微球可高效转染原代培养的兔软骨细胞,可以作为今后进一步体外、体内实验的首选转染载体。     

壳聚糖携载质粒纳米微球体外转染兔关节软骨细胞的实验研究

目的:研究携载质粒的不同分子量的壳聚糖纳米微球的包裹率和保护DNA的能力,镜下观察其大小和形态,观察其对原代兔关节软骨细胞的转染效率。方法:利用酶消化法消化3周龄新西兰大白兔的关节软骨,贴壁培养原代兔关节软骨细胞。购买相对分子量在5K和800K之间的八种壳聚糖,利用表达增强型绿色荧光蛋白的质粒(pEGFP)作报告基因,通过复合凝聚法制备壳聚糖-质粒纳米微球。琼脂糖凝胶电泳、紫外分光光度计分析不同N/P比值对不同分子量壳聚糖和质粒的结合能力及包封率的影响;纳米粒度仪、透射电子显微镜和环境扫描电子显微镜考察纳米微球的粒径分布和形态;荧光显微镜观察壳聚糖纳米微球介导pEGFP在体外培养的兔关节软骨细胞中的表达情况;流失细胞仪计算具体转染效率。结果:①N/P值为4及4以上时,各分子量的壳聚糖可完全包裹质粒成球;N/P值为2时,分子量为5K、50K、85K仅部分包裹质粒,其余可完全包裹;N/P值为1时,各壳聚糖均与质粒部分包裹;N/P值为0.25时,各壳聚糖均与质粒完全分离。②纳米粒度仪分析得出:N/P值为4时,各分子量的壳聚糖纳米微球的平均粒径均在1微米以下,③透射电子显微镜和扫描电子显微镜均可观察到球形或不规则形的大小不同的微球。荧光显微镜可大致观察到绿色荧光蛋白在软骨细胞内表达的表达情况。④流式细胞仪得出具体转染效率,分子量为170K、250K和800K的壳聚糖纳米微球的转染效率均高于5K、50K和85K的壳聚糖纳米微球,其中800K的壳聚糖纳米微球与脂质体相当(差异有统计学意义,P<0.05)。结论:与脂质体相比,N/P比值为4时,相对分子量为800k的壳聚糖纳米微球可高效转染原代培养的兔软骨细胞,可以作为今后进一步体外、体内实验的首选转染载体。     

载氢-纳米氧化铈微泡对小鼠造血系统抗辐射作用的分析

为探讨载氢-纳米氧化铈微泡对小鼠辐射损伤的防护作用。本研究检测载氢-纳米氧化铈微泡的表征,并将60只BALB/c小鼠随机分为正常对照组、照射对照组、载氢-纳米氧化铈微泡组。小鼠经6Gy x射线一次性全身照射(剂量率2 Gy/min)。于照射后3 d和8 d处死小鼠,检测其外周血细胞数、脾脏和胸腺指数、骨髓和脾脏组织病理学变化。结果显示,照射后3 d和8 d,与正常对照组相比,载氢-纳米氧化铈微泡组和照射对照组的白细胞均明显下降,相比照射对照组,载氢-纳米氧化铈微泡组有改善(p<0.05或p<0.01);而载氢-纳米氧化铈微泡组和照射对照组的红细胞数和血红蛋白均略有下降,但差异无统计学意义。与正常对照组相比,微泡组的胸腺指数、脾脏指数均有下降,和照射对照组相比,载氢-纳米氧化铈微泡组的胸腺指数明显改善(p<0.05或p<0.01)。照射后3 d,与正常对照组相比,照射对照组的骨髓细胞较少,存在细胞碎片,载氢-纳米氧化铈微泡组骨髓细胞数量略有减少,存在细胞核松散现象。而照射后8 d,与正常对照组相比,照射对照组的骨髓细胞几乎找不到,载氢-纳米氧化铈微泡组骨髓细胞有一定数量,存在细胞凋亡现象。本研究表明,载氢-纳米氧化铈微泡通过保护造血组织、改善造血功能,对机体起到一定的辐射防护作用。     

用壳聚糖纳米磁性微球纯化血红细胞超氧化物歧化酶

本研究旨在用壳聚糖-聚丙烯酸纳米磁性微球纯化血红细胞超氧化物歧化酶。采用了接枝共聚法,以K2S2O8为引发剂,使壳聚糖(CTS)与聚丙烯酸(PAA)进行自由接枝共聚合成含有两性基团(-NH3,-COOH)的壳聚糖-聚丙烯酸纳米微球。化学共沉淀法制备Fe3O4磁流体,以戊二醛为交联剂,制备壳聚糖-聚丙烯酸纳米磁性微球。用傅里叶变换红外光谱仪对磁性微球结构进行检测。JEM-4000EX电镜技术对微球粒径,形貌进行表征。SOD试剂盒测定各步骤Cu-ZnSOD酶活性。结果表明,壳聚糖-聚丙烯酸纳米磁性微球有较好的粒径分布、磁响应性及蛋白吸附特性。纯化后酶比活性达6 727 U/mg,产品得率21.1%,活性回收85.7%。壳聚糖-聚丙烯酸纳米磁性微球经血液纯化血红细胞SOD具有可再生性、易操作性,其纯化效果取决于金属Cu2+的螯合程度。     

经皮给药载体载MD-CPT透明质酸纳米乳的细胞吞噬与体内药代动力学研究

本文在研究制备了包载10,11-亚甲二氧基喜树碱(MD-CPT)的透明质酸纳米乳(HANs)经皮给药系统的基础上,进一步研究了载MD-CPT透明质酸纳米乳的细胞吞噬,并进行了体内药代动力学分析.通过优化制备条件,得到了皮肤渗透性良好的缓释剂型.从CLSM观察到药物被细胞摄入并传递入细胞核,同时,载药纳米乳的细胞吞噬效率呈时间依赖性,不同细胞株HSF、HUVES、MCF-7、KF的细胞吞噬率略有不同.用Rhodanmine B标记HANs,通过荧光显微镜观察到载药纳米乳透过角质层到达真皮层的拟动态过程.利用HPLC检测MD-CPT血药浓度,测得经皮给药半衰期T1/2是静脉注射的3.6倍,肌肉注射的1.6倍,体内药物滞留时间显著增加;血药浓度峰谷值差异小,曲线平缓,说明经皮给药能保证血药浓度呈现可控的持续性.最终通过活体成像系统和组织切片荧光显微镜,直观地反映出经皮给药后药物在大鼠体内的分布情况和各组织器官药物含量,确定载药纳米乳主要采取胞间渗透的扩散方式,在局部给药的区域滞留时间较长,有利于对浅表性的病灶区持续给药,延长药效,而剩余的MD-CPT和解离的HANs都进入了血液循环,最终通过新陈代谢被排出体外.为无创型HANs经皮给药系统应用于浅表性肿瘤治疗提供了理论基础.     

Miniaturization in Pharmaceutical Extrusion Technology: Feeding as a Challenge of Downscaling

In recent years, extrusion technology has shifted the focus of pharmaceutical research due to versatile applications like pelletization, bioavailability improvement or manipulation of solid-state properties of drugs, continuous granulation, and the development of novel solid dosage forms. Meanwhile, a major effort has been devoted to the miniaturization of equipment in pharmaceutical extrusion technology, particularly with regard to the requirements of the development of new chemical entities and formulations. In the present study, a lab-scale twin-screw extruder was investigated in order to determine the limitations imposed by the feeding systems. The wet extrusion process was considered as challenging because both a powder and a liquid feeder have to be considered. Initially, the accuracy and uniformity of the powder and liquid feeder were tested independently of the extrusion process. After modification of the powder feeder, both feeders were investigated in conjunction with extrusion. Based on this, an optimization of the liquid feeder was required and completed. Both feeder modifications reduced the variability of the moisture content in the extrudates 10-fold. This led to a reliable small-scale extrusion process.     

Excipient Stability in Oral Solid Dosage Forms: A Review

The choice of excipients constitutes a major part of preformulation and formulation studies during the preparation of pharmaceutical dosage forms. The physical, mechanical, and chemical properties of excipients affect various formulation parameters, such as disintegration, dissolution, and shelf life, and significantly influence the final product. Therefore, several studies have been performed to evaluate the effect of drug-excipient interactions on the overall formulation. This article reviews the information available on the physical and chemical instabilities of excipients and their incompatibilities with the active pharmaceutical ingredient in solid oral dosage forms, during various drug-manufacturing processes. The impact of these interactions on the drug formulation process has been discussed in detail. Examples of various excipients used in solid oral dosage forms have been included to elaborate on different drug-excipient interactions.     

三嵌段聚合物在药物制剂中的应用研究进展

三嵌段聚合物系由2 种或2 种以上不同化合物通过聚合反应而合成的一种新型多功能两亲性载体材料,在水溶液中呈现优良的自组装性能。其用作药物载体时,可依据需求,通过改变其组成和结构而使其拥有温度敏感、pH 敏感、磁敏感等多种特性,将其制成适宜剂型,能达到改善药物的溶解性等理化性质以及靶向性、缓控释性和生物利用度的目的,其在药物制剂领域具有广阔的应用前景。简介各种类型的三嵌段聚合物,着重概述近年来三嵌段聚合物在不同制剂剂型中的应用研究。     

Analysis of phenothiazine neuroleptics by means of non-aqueous titrimetry]

Phenothiazine neuroleptic drugs, either as pure compounds or in pharmaceutical dosage forms have been quantitatively assayed by nonaqueous titrimetry. Suggested procedure is applicable to basic drugs and their corresponding salts without prior cleanup overcoming the interferences due to excipients.     

Identification and dosage of psychopharmaceutical phenothiazine drugs by HPLC

Phenothiazine neuroleptic drugs have been assayed by "Soap Chromatography", a new technique for separation of ionizable materials. The suggested procedure is applicable to a number of drugs either as pure compounds or in pharmaceutical dosage forms without prior cleanup.     

Investigation of cytochromes P450 in myxobacteria: excavation of cytochromes P450 from the genome of Sorangium cellulosum So ce56

The exploitation of cytochromes P450 for novel biotechnological application and for the investigation of their physiological function is of great scientific interest in this post genomic era, where an extraordinary biodiversity of P450 genes has been derived from all forms of life. The study of P450s in the myxobacterium Sorangium cellulosum strain So ce56, the producer of novel secondary metabolites of pharmaceutical interest is the research topic, in which we were engaged since the beginning of its genome sequencing project. We herein disclosed the cytochrome P450 complements (CYPomes) of spore-forming myxobacterial species, Stigmatella aurantiaca DW4/3-1, Haliangium ochraceum DSM 14365 and Myxococcus xanthus DK1622, and their potential pharmaceutical significance has been discussed.     

Zein as a Pharmaceutical Excipient in Oral Solid Dosage Forms: State of the Art and Future Perspectives

Zein is the main storage protein of corn and it has several industrial applications. Mainly in the last 10–15 years, zein has emerged as a potential pharmaceutical excipient with unique features. Zein is a natural, biocompatible and biodegradable material produced from renewable sources. It is insoluble, yet due to its amphiphilic nature, it has self-assembling properties, which have been exploited for the formation of micromicroparticle and nanoparticle and films. Moreover, zein can hydrate so it has been used in swellable matrices for controlled drug release. Other pharmaceutical applications of zein in oral drug delivery include its incorporation in solid dispersions of poorly soluble drugs and in colonic drug delivery systems. This review describes the features of zein significant for its use as a pharmaceutical excipient for oral drug delivery, and it summaries the literature relevant to macroscopic zein-based oral dosage forms, i.e. tablets, capsules, beads and powders. Particular attention is paid to the most novel formulations and applications of zein. Moreover, gaps of knowledge as well as possible venues for future investigations on zein are highlighted.     

3D-Printed Network Structures as Controlled-Release Drug Delivery Systems: Dose Adjustment,API Release Analysis and Prediction

3D printing evolved as a promising technique to improve individualization of drug therapy. In particular, when printing sustained release solid dosage forms, as for instance implants, inserts, and also tablets, estimation of the drug release profile in vivo is necessary. In most cases, corresponding analyses cannot be performed at hospital or community pharmacies. Therefore, the present study aimed to develop a sustained release drug delivery system produced via 3D printing, which allows dose adaption and estimation of drug release at the same time. Filaments as feedstock for the printer were produced via hot-melt extrusion and consisted of Eudragit® RL as sustained release polymer, 30% theophylline as model active pharmaceutical ingredient, and stearic acid as solid plasticizer. Assuming that the surface/mass ratio was constant, network structures of different densities were printed as novel solid dosage form. Their weight (263 to 668 mg), thereby their dose, and surface area, determined using X-ray microcomputed tomography, showed a linear correlation with the fill density. The specific surface area of the network hardly varied with changing fill density. Dissolution studies showed a slower drug release for dosage forms with a denser network. Higuchi’s model was used for prediction of drug release and showed limited applicability due to different release kinetics for different fill densities. However, using linear interpolation for the prediction resulted in good RMSEP values between 1.4 and 3.7%. These findings might be useful to enable customized production of sustained release solid dosage forms via 3D printing in hospital and community pharmacies in the future.     

REAL-TIME POLYMERASE CHAIN REACTION FOR DETECTION OF STAPHYLOCOCCUS AUREUS AND PSEUDOMONAS AERUGINOSA IN PHARMACEUTICAL PRODUCTS FOR TOPICAL USE

Real-time PCR assays, based on LightCycler^TM hybridization probes technology, originally developed for detection of Staphylococcus aureus and Pseudomonas aeruginosa in clinical samples, were adapted to pharmaceutical products for topical use. After optimization experiments, the applicability of optimized PCR assays was assessed by testing 34 different pharmaceutical products for topical use in parallel with standard microbiological protocol according to European Pharmacopoeia. To reveal any problematic substances, which might inhibit PCR reaction, pharmaceutical products with as much different dosage forms as possible and of different composition were selected. Complete concordance between PCR and standard microbiological protocol results was obtained on a wide spectrum of pharmaceutical products. The adapted PCR assays can detect 1–10 CFU of both bacteria per gram or milliliter of pharmaceutical product in 26 h (including 24-h enrichment), whereas standard microbiological methods require 5–7 days. Real-time PCR assays proved to be efficient tools for rapid screening of S. aureus and P. aeruginosa in pharmaceutical products for topical use.